Erdosteine

Erdosteine
Clinical data
AHFS/Drugs.com International Drug Names
Routes of
administration		 oral, inhalation
ATC code R05CB15 (WHO)
Pharmacokinetic data
Protein binding 65%
Metabolism hepatic
Biological half-life 1-3 hours
Identifiers
CAS Number 84611-23-4 YesY
PubChem (CID) 65632
ChemSpider 59073 YesY
UNII 76J0853EKA YesY
KEGG D07383 YesY
ChEMBL CHEMBL1697744
ECHA InfoCard 100.169.984
Chemical and physical data
Formula C8H11NO4S2
Molar mass 249.309 g/mol
3D model (Jmol) Interactive image
  (verify)

Erdosteine is a mucolytic. Specifically it is a thiol derivative developed for the treatment of chronic obstructive bronchitis, including acute infective exacerbation of chronic bronchitis. Erdosteine contains two blocked sulfhydryl groups which are released following first-pass metabolism. The three active metabolites exhibit mucolytic and free radical scavenging activity. Erdosteine modulates mucus production and viscosity and increases mucociliary transport, thereby improving expectoration. It also exhibits inhibitory activity against the effects of free radicals produced by cigarette smoke.

Clinical studies in patients with chronic obstructive lung disease have demonstrated the efficacy and tolerability of erdosteine.[1] Erdosteine 300 mg twice daily reduced cough (both frequency and severity) and sputum viscosity more quickly and more effectively than placebo and reduced the adhesivity of sputum more effectively than bromhexine 30 mg twice daily.

Co-administration of erdosteine and amoxicillin in patients with acute infective exacerbation of chronic bronchitis resulted in higher concentrations of the antibiotic in the sputum, leading to earlier and more pronounced amelioration of clinical symptoms compared with placebo.

Erdosteine is associated with a low incidence of adverse events, most of which are gastrointestinal and generally mild. The LD50 is very high, 3,500-5,000 mg/kg.

Brand names

Europe:

Other regions:

References

  1. ↑ Drugs Exp Clin Res. 2004;30(4):143-52.The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study
This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.